NCT04909450: A trial that was reported late by Claris Biotherapeutics, Inc.
This trial has reported, although it was 114 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT04909450 |
|---|---|
| Title | A Multi-Center, Randomized, Double-Masked, Vehicle-Controlled, Parallel-Group, Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Stage 2 and 3 Neurotrophic Keratitis Subjects |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Aug. 24, 2021 |
| Completion date | May 7, 2024 |
| Required reporting date | May 7, 2025, midnight |
| Actual reporting date | Aug. 29, 2025 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | 114 |